Genetronics Biomedical Corporation has entered into a second collaborative agreement with Chiron Corporation to explore the feasibility of using electroporation, Genetronics' platform technology, to deliver certain DNA vaccines into cells in vivo.

"We are pleased to engage in another significant collaboration with Chiron Corporation to validate the efficacy of our proprietary electroporation platform technology for applications in DNA vaccination," said Babak Nemati, Vice-President of Corporate Development. "Our joint efforts with the scientists at Chiron have been advancing very well, and we are very encouraged by the research results obtained to date."

Electroporation involves the use of extremely brief, intense, pulsed electric fields to temporarily permeabilize cell membranes, creating transient pores, which allow the entry of various types of molecules such as DNA and proteins into the cell. Genetronics is the world leader in producing electroporation instrumentation and electrodes for use in clinical and non-clinical settings. Electroporation is widely used in vitro to effectively deliver DNA into eukaryotic cells and bacteria.